Signs and symptoms of Graves' disease explained

The signs and symptoms of Graves' disease generally result from the direct and indirect effects of hyperthyroidism, although they can also be caused by other thyroidal conditions, such as Graves' ophthalmopathy, goitre and pretibial myxedema. These clinical manifestations can involve virtually every system in the body.

The mechanisms that mediate these effects are not well understood. The severity of the signs and symptoms of hyperthyroidism is related to the duration of the disease, the magnitude of the thyroid hormone excess, and the patient's age.

Although the majority of patients experience significant improvement and remission after proper medical care, health care providers should be aware of variability in individual response to hyperthyroidism and individual sensitivity to thyroid hormone fluctuations.[1] Patients with Graves' disease can also undergo periods of hypothyroidism (inadequate production of thyroid hormone; see symptoms of hypothyroidism), due to the challenges of finding the right dosage of thyroid hormone suppression and/or supplementation. The body's need for thyroid hormone can also change over time, such as in the first months after radioactive iodine treatment (RAI). Thyroid autoimmune diseases can also be volatile, as hyperthyroidism can interchange with hypothyroidism and euthyroidism.[2]

General symptoms

Skin/Hair/Nails

Nose/Sinuses

Neck

Eyes

Respiratory/Cardiac

Gastrointestinal

Musculoskeletal

Neurologic

Endocrine

Psychiatric

Other

Effects on the skeleton

Overt hyperthyroidism caused by Grave's Disease is associated with accelerated bone remodeling (resulting in increased porosity of cortical bone and reduced volume of trabecular bone). This can lead to reduced bone density and eventually osteoporosis as well as increased fracture rates. The increased hip fracture rates later in life in turn cause excess late mortality. The changes in bone metabolism are connected with negative calcium balance, an increased excretion of calcium and phosphorus in the urine (hypercalciuria) and stool, and, rarely, hypercalcemia.[13] In hyperthyroidism, the normal cycle duration of bone resorption of approximately 200 days is halved, and each cycle is associated with a 9.6 percent loss of mineralized bone. In hypothyroidism, cycle length approximates 700 days and is associated with a 17 percent increase in mineralized bone.[17]

The extent of the reduction in bone density in most studies is 10–20%. The clinical manifestations on bone differ depending on the age of the patient. Postmenopausal woman are most sensitive to accelerated bone loss from thyrotoxicosis. Accelerated bone growth in growing children can increase ossification in the short term, but generally results in short-stature adults compared with the predicted heights.

If thyrotoxicosis is treated early, bone loss can be minimized. The level of calcium in the blood can be determined by a simple blood test, and a Dual Energy X-Ray Absorptiometry scan can help determine patient bone density relative to the rest of the population. There are many medications that can help to rebuild bone mass and to prevent further bone loss, such as Bisphosphonates. Risedronate treatment has been demonstrated to help restore bone mass in osteopenia/osteoporosis associated with Graves' disease.[18] Nevertheless, weight-bearing exercises, a balanced diet, calcium intake of about 1500 mg a day and enough vitamin D, are of course elementary foundations.

Eye symptoms

Hyperthyroidism almost always causes general eye symptoms like dryness and irritation, regardless of what the cause of the hyperthyroid state is. However, these need to be distinguished from Graves' ophthalmopathy, which can only occur in patients who have Graves' disease. (It may also, rarely, be seen in Hashimoto's thyroiditis, primary hypothyroidism, and thyroid cancer).[19]

About 20–25% of patients with Graves' disease will suffer from clinically obvious Graves' ophthalmopathy, and not just from the eye signs of hyperthyroidism. Only 3 to 5% will develop severe ophthalmopathy.[20] However, when subjected to closer inspection (e.g. by magnetic resonance imaging of the orbits) many more patients have evidence of ophthalmopathy. It is estimated that for every 100,000 persons, 16 women and 3 men have Graves' ophthalmopathy every year.[21]

Although it is true that in most patients ophthalmopathy, goiter, and symptoms of thyrotoxicosis appear more or less coincidentally, it is also true that in certain cases eye signs may appear long before thyrotoxicosis is evident, or become worse when the thyrotoxicosis is subsiding or has been controlled by treatment.[5] In approximately 20% of ophthalmopathy patients, ophthalmopathy appears before the onset of hyperthyroidism, in about 40% concurrently, and in about 20% in the six months after diagnosis.[22] In the remainder, the eye disease first becomes apparent after treatment of the hyperthyroidism, more often in patients treated with radioiodine.[23]

It can sometimes be difficult to distinguish between eye symptoms due to hyperthyroidism and those due to Graves' antibodies, because the two often occur coincidentally. What can make things particularly difficult, is that many patients with hyperthyroidism have lid retraction, which leads to stare and lid lag (due to contraction of the levator palpebrae muscles of the eyelids). This stare may then give the appearance of protruding eyeballs (proptosis), when none in fact exists. This subsides when the hyperthyroidism is treated.

Due to Graves' ophthalmopathy

See main article: Graves' ophthalmopathy. Graves' ophthalmopathy is characterized by inflammation of the extraocular muscles, orbital fat and connective tissue. It results in the following signs, which can be extremely distressing to the patient:[5]

Due to hyperthyroidism

In the absence of Graves' ophthalmopathy, patients may demonstrate other ophthalmic symptoms and signs due to hyperthyroidism:

Neuropsychological manifestations

Several studies have suggested a high prevalence of neuropsychiatric disorders and mental disorder symptoms in Graves' disease (and thyroid disease in general), which are similar to those in patients with organic brain disease.[25] [26] [27] [28] [29] These manifestations are diverse, affecting the central and peripheral nervous systems. The vast majority of patients with hyperthyroidism meet criteria for some psychiatric disorders,[25] and those with milder presentations are probably not entirely free of mental symptoms such as emotional lability, tension, depression and anxiety.[25] Anxiety syndromes related to hyperthyroidism are typically complicated by major depression and cognitive decline, such as in memory and attention.[30] Some studies contradict the psychological findings. For example, a large 2002 study found "no statistical association between thyroid dysfunction, and the presence of depression or anxiety disorder."[31] In one study on hospitalised elderly patients, over half had cognitive impairment with either dementia or confusion.[32] However, a controlled study on 31 Graves' disease patients found that while patients had subjective reports of cognitive deficits in the toxic phase of Graves' thyrotoxicosis, formal testing found no cognitive impairment and suggested the reported symptoms may reflect the affective and somatic manifestations of hyperthyroidism.[33] Notably, a literature review of 2006 notes methodology issues in the consistency of Graves' disease diagnostic criteria, which might explain the apparently contradicting findings. These researchers found many reports about residual complaints in patients who were euthyroid after treatment, with a high prevalence of anxiety disorders and bipolar disorder, as well as elevated scores on scales of anxiety, depression and psychological distress.[25] In a 1992 study, a significant proportion of the 137 questioned patients with Graves' disease reported – among other things – increased crying (55%), being easily startled (53%), being tired all the time (47%), a significant decrease in social activity (46%), feelings of being out of control (45%), feelings of hopelessness (43%), loss of sense of humor (41%), loss of interest in things they formerly enjoyed (39%), not being able to 'connect' with others (34%).[34]

Several studies point out that the severity of psychiatric symptoms could easily result in an inappropriate referral to a psychiatrist prior to the diagnosis of hyperthyroidism.[35] [36] Consequently, undiagnosed hyperthyroidism sometimes results in inappropriate use of psychotropic medications; prompt recognition of hyperthyroidism (or hypothyroidism) through thyroid function screening is therefore recommended in the evaluation of patients with psychiatric symptoms.[36] [37] Naturally, the management of patients would be improved by collaboration between an endocrinologist and a psychiatrist.[38]

Overall, reported symptoms vary from mild to severe aspects of anxiety or depression, and may include psychotic and behavioral disturbances:

Treatment of hyperthyroidism typically leads to improvement in cognitive and behavioral impairments.[33] Agitation, inattention, and frontal lobe impairment may improve more rapidly than other cognitive functions. However, several studies confirm that a substantial proportion of patients with hyperthyroidism have psychiatric disorders or mental symptoms and decreased quality of life even after successful treatment of their hyperthyroidism.[27]

Effects on pre-existing psychiatric disorders

Patients with pre-existing psychiatric disorders, will experience a worsening of their usual symptoms, as observed by several studies. A study of 1999 found that Graves' disease exacerbated the symptoms of Tourette's disorder and attention-deficit hyperactivity disorder (ADHD), and points out that the lack of diagnosis of the Graves' disease compromised the efficacy of the treatment of these disorders.[46] Patients who are known to have a convulsive disorder may become more difficult to control with the usual medications, and seizures may appear in patients who have never previously manifested such symptoms.[5]

Sub-clinical hyperthyroidism

In sub-clinical hyperthyroidism, serum TSH is abnormally low, but T4- and T3-levels fall within laboratory reference ranges.[47] It primarily affects the skeleton and the cardiovascular system (abnormalities in other systems have also been reported), in a similar but less severe and less frequent way than overt hyperthyroidism does. It can alter cardiac function, with increased heart rate, increased left ventricular mass index, increased cardiac contractility, diastolic dysfunction, and induction of ectopic atrial beats. Long-term mild excess of thyroid hormone can thus cause impaired cardiac reserve and exercise capacity.[5] In a large population-based study of 2008, the odds of having poorer cognitive function were greater for sub-clinical hyperthyroidism than for stroke, diabetes mellitus, and Parkinson's disease.[48] Sub-clinical hyperthyroidism might modestly increase the risk of cognitive impairment and dementia.[49] Subclinical hyperthyroidism in pregnancy is associated with an increased risk of pre-eclampsia, low birth weight, miscarriage and preterm birth.[50] Propylthiouracil is the preferred treatment of hyperthyroidism (both overt and subclinical) in the first trimester of pregnancy as it is associated with less birth defects than methimazole.

A possible explanation for the mental symptoms of sub-clinical thyroid disease, might be found in the fact that the brain has among the highest expression of THR's, and that neurons are often more sensitive than other tissues to thyroid abnormalities, including sub-clinical hyperthyroidism and thyrotoxicosis.[51] [52] [53] In a 1996 survey study respondents reported a significant decline in memory, attention, planning, and overall productivity from the period 2 years prior to Graves' symptoms onset to the period when hyperthyroid.[27] Also, hypersensitivity of the central nervous system to low-grade hyperthyroidism can result in an anxiety disorder before other Graves' disease symptoms emerge. E.g., panic disorder has been reported to precede Graves' hyperthyroidism by 4 to 5 years in some cases, although it is not known how frequently this occurs.[54]

However, while clinical hyperthyroidism is associated with frank neuropsychological and affective alterations, the occurrence of these alterations and their treatment in mild and sub-clinical hyperthyroidism remains a controversial issue. Regardless of the inconsistent findings, a 2007 study by Andersen et al. states that the distinction between sub-clinical and overt thyroid disease is in any case somewhat arbitrary.[55] Sub-clinical hyperthyroidism has been reported in 63% of euthyroid Graves' disease,[56] but only in 4% of cases where Graves' disease was in remission.[57]

Subclinical hyperthyroidism has an 8% risk of converting to overt hyperthyroidism at 1 year, and a 26% risk at 5 years.

Children and adolescents

Hyperthyroidism has unique effects in children on growth and pubertal development, e.g. causing epiphyseal maturation. In growing children, accelerated bone growth from hyperthyroidism can increase osteogenesis in the short term, but generally results in short-stature adults compared with the predicted heights. Pubertal development tends to be delayed, or slowed. Girls who have undergone menarche may develop secondary amenorrhea. Hyperthyroidism is associated with high sex hormone-binding globulin (SHBG), which may result in high serum estradiol levels in girls and testosterone levels in boys. However, unbound or free levels of these hormones are decreased. Hyperthyroidism before the age of four may cause neurodevelopmental delay. A study by Segni et al. suggests that permanent brain damage can occur as a result of the illness.[5] [58]

Ophthalmopatic findings are more common but less severe in children (severe infiltrative exophthalmos is virtually unknown before mid-adolescence), but besides that, many of the typical clinical features of hyperthyroidism in children and adolescents are similar to those in adults.[5] An important difference between children and adults with Graves' disease, is that children have not yet developed like adults have (psychological and physiological), and that they are a lot more dependent on their environment. The encephalopathy will have profound effects on children's developing personalities and developing relationship with their environment. Disturbments in bodily development further complicates matters. The consequences for the development and the somatic and psychological well-being of the child can be very radical and sometimes irreversible. The earlier a person is affected by thyroid disease, the more the development of personality is affected and the bigger the delay from their potential development level. The child gets behind in its cognitive, emotional and sexual growth, which, by itself, also influences its processing abilities of the endocrine disease.[2]

Children with hyperthyroidism tend to have greater mood swings and disturbances of behavior, as compared with adults. Their attention span decreases, they are usually hyperactive and distractible, they sleep poorly, and their school performance deteriorates. Because devastating personality and emotional changes often appear in the child or adolescent with Graves' disease, many hyperthyroid children are (similar to many adults) referred to a developmental specialist or child psychiatrist before the presence of hyperthyroidism is suspected.[5]

Older patients

In older patients, emotional instability may be less evident, or depression may occur, and the symptoms and signs are manifestly circulatory. In many, the thyroid is not readily palpable.[5] Symptoms such as rapid heart rate, shortness of breath on exertion, and edema may predominate. Older patients also tend to have more weight loss and less of an increase in appetite. Thus anorexia in this group is fairly frequent, as is constipation.[5] Elderly patients may have what is called "apathetic thyrotoxicosis", a state in which they have less and less severe symptoms, except for weakness, depression and lethargy (making it even more prone to escape diagnosis).

Graves' disease and work

Considering the many signs and symptoms, the generally delayed diagnosis, and the possibility of residual complaints after treatment, it is little wonder that a significant number of people with Graves' disease have difficulty keeping their job. One study found that of 303 patients successfully treated for hyperthyroidism (77% had Graves' disease) 53% dealt with lack of energy. About one-third were unable to resume their customary work, mainly due to persistent mental problems.[25] [59] In their 1986 study of 26 patients (10 years after successful treatment of hyperthyroidism), Perrild et al. note that four patients had been granted disability pensions on the basis of intellectual dysfunction.[60] Between 2006 and 2008, Ponto et al. surveyed 250 Graves' disease patients. Of these, 36% were written off sick and 5% even had to take early retirement. In the same study, 34% of 400 questioned physicians reported treating patients with fully impaired earning capacity.[61]

Patients can and do recover with appropriate therapy while continuing to work, but more rapid and certain progress is made if a period away from the usual occupation can be provided.[18] Two important considerations are adequate rest and attention to nutrition.[18]

Notes and References

  1. Web site: Druckerhttp D . Hyperthyroidism . MyThyroid.com . 2005 . 2010-05-03.
  2. Psychische stoornissen bij endocriene zieken, 1983, C. van der Meer en W. van Tilburg (red.)
  3. Cutaneous manifestations of thyroid disease. Heymann WR, J Am Acad Dermatol. 1992;26(6) 885.
  4. Surgical management of multinodular goiter with compression symptoms. Ríos A, Rodríguez JM, Canteras M, Galindo PJ, Tebar FJ, Parrilla P, Arch Surg. 2005;140(1) 49; Compression syndromes caused by substernal goitres. Anders HJ, Postgrad Med J. 1998;74(872) 327.
  5. "Graves' Disease and the Manifestations of Thyrotoxicosis" – Leslie l. De Groot, Thyroid Disease Manager, Chapter 10 (http://www.thyroidmanager.org/chapter/graves-disease-and-the-manifestations-of-thyrotoxicosis/)
  6. Hyperthyroidism and the Heart . Methodist Debakey Cardiovascular Journal . 2017 . 28740583 . Osuna . P. M. . Udovcic . M. . Sharma . M. D. . 13 . 2 . 60–63 . 10.14797/mdcj-13-2-60 . 5512680 .
  7. Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH . 2000 . Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study . Journal of Neurology, Neurosurgery & Psychiatry . 68 . 6 . 750–755 . 10.1136/jnnp.68.6.750 . 1736982 . 10811699.
  8. Henderson JM, Portmann L, Van Melle G, Haller E, Ghika JA . 1997 . Propranolol as an adjunct therapy for hyperthyroid tremor . European Neurology . 37 . 3 . 182–5 . 10.1159/000117431 . 9137929.
  9. Kim HT, Edwards MJ, Lakshmi Narsimhan R, Bhatia . 2005 . a clinical lesson . Parkinsonism & Related Disorders . 11 . 5 . 331–2 . 10.1016/j.parkreldis.2005.01.009 . 15970453.
  10. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH, J Neurol Neurosurg Psychiatry. 2000;68(6) 750; Electromyographic and histological findings in the muscles of patients with thyrotoxicosis. HAVARD CW, CAMPBELL ED, ROSS HB, SPENCE AW, Q J Med. 1963;32:145; Electromyography in thyrotoxicosis. Ramsay ID, Q J Med. 1965;34(135) 255.
  11. Nordyke RA, Gilbert FI Jr, Harada AS . 1988 . Graves' disease. Influence of age on clinical findings . Arch Intern Med . 148 . 3 . 626–31 . 10.1001/archinte.1988.00380030132023 . 3341864.
  12. The hypothalamic-pituitary-testicular axis in thyrotoxicosis. Kidd GS, Glass AR, Vigersky RA, J Clin Endocrinol Metab. 1979;48(5) 798.
  13. Web site: Mathur . Ruchi . 2014-12-01 . Thyroid Disease, Osteoporosis, and Calcium . 2017-10-07 . MedicineNet.
  14. Norbert Gleicher . Gleicher N, Weghofer A, Barad DH . Apr 2011 . Do chromosomally abnormal pregnancies really preclude autoimmune etiologies of spontaneous miscarriages? . Autoimmunity Reviews . 10 . 6 . 361–3 . 10.1016/j.autrev.2010.12.004 . 21195806.
  15. Gleicher N . December 2010 . Does the immune system induce labor? Lessons from preterm deliveries in women with autoimmune diseases . Clinical Reviews in Allergy & Immunology . 39 . 3 . 194–206 . 10.1007/s12016-009-8180-8 . 19844811 . 37559462.
  16. A survey study of neuropsychiatric complaints in patients with Graves' disease. Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AJ Jr, J Neuropsychiatry Clin Neurosci. 1996;8(2) 181.
  17. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Eriksen EF, Endocr Rev. 1986;7(4) 379.
  18. Chapter 11. Diagnosis and Treatment of Graves' Disease Leslie J. De Groot, MD Professor of Medicine – http://www.thyroidmanager.org/chapter/diagnosis-and-treatment-of-graves-disease/ Updated: March 5, 2008
  19. Şahlı . Esra . Gündüz . Kaan . April 2017 . Thyroid-associated Ophthalmopathy . Turkish Journal of Ophthalmology . 47 . 2 . 94–105 . 10.4274/tjo.80688 . 2149-8695 . 5384127 . 28405484.
  20. Graves' ophthalmopathy: a preventable disease? Luigi Bartalena, Claudio Marcocci and Aldo Pinchera1 – European Journal of Endocrinology (2002) 146 457–461
  21. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA . 1995 . The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota . American Journal of Ophthalmology. 120 . 4. 511–7 . 10.1016/s0002-9394(14)72666-2. 7573310 .
  22. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA . 1996 . Chronology of Graves' ophthalmopathy in an incidence cohort . American Journal of Ophthalmology. 121 . 4. 426–34 . 10.1016/S0002-9394(14)70439-8 . 8604736 .
  23. Tallstedt L, Lundell G, Tørring O, Wallin G, Ljunggren JG, Blomgren H, Taube A . 1992 . Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism . New England Journal of Medicine. 326 . 26. 1733–8 . 10.1056/nejm199206253262603. 1489388 . free .
  24. Ponto KA, Pitz S, Pfeiffer N, Hommel G, Weber MM, Kahaly GJ . Quality of life and occupational disability in endocrine orbitopathy . Deutsches Ärzteblatt Online. 106 . 17 . 283–9 . April 2009 . 19547630 . 2689575 . 10.3238/arztebl.2009.0283 . Pitz . Pfeiffer . Hommel . Weber . Kahaly .
  25. Bunevicius R, Prange AJ . Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options . CNS Drugs. 20 . 11 . 897–909 . 2006 . 17044727 . 10.2165/00023210-200620110-00003. Prange Jr . 20003511 .
  26. 10.1159/000026545 . Prevalence of Psychiatric Disorders in Thyroid Diseased Patients . G.P.A. Placidia, M. Boldrinia, A. Patronellia, E. Fioreb, L. Chiovatob, G. Perugia, D. Marazzitia . Neuropsychobiology. 1998 . 38 . 222–5 . 9813461 . 4. Boldrini . Patronelli . Fiore . Chiovato . Perugi . Marazziti . 2158/789562 . 25689764 . free .
  27. Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange AJ . A survey study of neuropsychiatric complaints in patients with Graves' disease . The Journal of Neuropsychiatry and Clinical Neurosciences. 8 . 2 . 181–5 . 1996 . 9081554 . 10.1176/jnp.8.2.181. Robinson . Thorner . Arruda . Prohaska . Prange Jr .
  28. Thyroid hormones, the brain, and affective disorders. Joffe RT, Sokolov ST. . Critical Reviews in Neurobiology. 1994 . 8 . 1–2 . 45–63 . 8124730. Sokolov .
  29. Attention disturbance in graves' disease . Alvarez . Psychoneuroendocrinology. 1983 . 8 . 4 . 451–4 . 6689536 . Gómez . A . Alavez . E . Navarro . D . 10.1016/0306-4530(83)90026-4. 19460006 .
  30. 10.1016/0163-8343(88)90084-9 . Trzepacz . PT . McCue . M . Klein . I . vanc . Levey . 1988 . GS . Greenhouse . J . A psychiatric and neuropsychological study of patients with untreated Graves' disease . General Hospital Psychiatry. 10 . 1. 49–55 . 3345907 .
  31. Engum A, Bjøro T, Mykletun A, Dahl AA . An association between depression, anxiety and thyroid function--a clinical fact or an artifact?. Acta Psychiatrica Scandinavica. 106 . 1 . 27–34 . July 2002. 12100345 . 10.1034/j.1600-0447.2002.01250.x. Bjøro. Mykletun. Dahl. 46316229.
  32. Martin FI, Deam DR . Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes . Medical Journal of Australia. 164 . 4 . 200–3 . February 1996 . 8604186 . 10.5694/j.1326-5377.1996.tb94135.x. Deam . 29800258 .
  33. Vogel A . Affective symptoms and cognitive functions in the acute phase of Graves' thyrotoxicosis . Psychoneuroendocrinology. 32 . 1 . 36–43 . January 2007 . 17097812 . 10.1016/j.psyneuen.2006.09.012 . vanc. Elberling TV. Hørding M. 3. Dock. J. Rasmussen. A. Feldtrasmussen. U. Perrild. H. Waldemar. G. 54416080 .
  34. Journal of Neuropsychiatry and clinical neurosciences, 1996, 8:181–185.
  35. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J . A psychiatric and neuropsychological study of patients with untreated Graves' disease . General Hospital Psychiatry. 10 . 1 . 49–55 . January 1988 . 3345907 . 10.1016/0163-8343(88)90084-9. McCue . Klein . Levey . Greenhouse .
  36. McGaffee J, Lippmann S, Barnes MA . Psychiatric presentations of hyperthyroidism . American Family Physician. 27 . 2 . 257–60 . February 1983 . 6687506 . Lippmann . Barnes .
  37. Steinberg PI . A case of paranoid disorder associated with hyperthyroidism . The Canadian Journal of Psychiatry. 39 . 3 . 153–6 . April 1994 . 8033020 . 10.1177/070674379403900306. 34764148 .
  38. Psychiatric Manifestations of Graves' Hyperthyroidism Pathophysiology and Treatment Options Robertas Bunevicius and Arthur J. Prange Jr – CNS Drugs. 2006;20(11) 897–909
  39. Awad AG. The Thyroid and the Mind and Emotions/Thyroid Dysfunction and Mental Disorders . Thyrobulletin. 7 . 2000 . 2010-05-06 . 3.
  40. Placidi GP . Prevalence of psychiatric disorders in thyroid diseased patients . Neuropsychobiology. 38 . 4 . 222–5 . November 1998 . 9813461 . 10.1159/000026545. vanc. Boldrini M. Patronelli A. 3. Fiore. E.. Chiovato. L.. Perugi. G.. Marazziti. D.. 2158/789562 . 25689764 . free.
  41. Psychische stoornissen bij endocriene zieken, 1983, C. van der Meer en W. van Tilburg (red.) suggests usually with an agitated streak, not a depression of the inhibited type
  42. Bunevicius R, Velickiene D, Prange AJ . Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease . General Hospital Psychiatry. 27 . 2. 133–9 . 2005 . 15763125 . 10.1016/j.genhosppsych.2004.10.002 . Velickiene . Prange Jr .
  43. The Thyroid Solution, Arem Ridha
  44. Hall RC . Psychiatric effects of thyroid hormone disturbance . Psychosomatics. 24 . 1 . 7–11, 15–8 . January 1983 . 6338551 . 10.1016/S0033-3182(83)73255-X.
  45. Mizukami K, Shiraishi H, Koizumi J . A Graves' disease of identical twins with mental disorder . Japanese Journal of Psychiatry and Neurology. 42 . 4 . 777–83 . December 1988 . 3074208 . 10.1111/j.1440-1819.1988.tb01166.x. Shiraishi . Koizumi . 35971791 .
  46. Woolston JL, Caracansi A . Case study: missed diagnosis and mistreatment of unrecognized comorbid Graves disease . Journal of the American Academy of Child & Adolescent Psychiatry. 38 . 7 . 861–4 . July 1999 . 10405504 . 10.1097/00004583-199907000-00016. Caracansi . free .
  47. Narrow Individual Variations in Serum T4 and T3 in Normal Subjects: A Clue to the Understanding of Subclinical Thyroid Disease Stig Andersen, Klaus Michael Pedersen, Niels Henrik Bruun and Peter Laurberg – The Journal of Clinical Endocrinology & Metabolism, 2007, Vol. 87, No. 3 1068–1072
  48. Ceresini G . Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study . Journal of the American Geriatrics Society. 57 . 1 . 89–93 . January 2009 . 19054181 . 2631617 . 10.1111/j.1532-5415.2008.02080.x . vanc. Lauretani F. Maggio M. 3. Ceda. Gian Paolo. Morganti. Simonetta. Usberti. Elisa. Chezzi. Carlo. Valcavi. Rita. Bandinelli. Stefania. 10.1.1.657.1067.
  49. Rieben. Carole. Segna. Daniel. da Costa. Bruno R.. Collet. Tinh-Hai. Chaker. Layal. Aubert. Carole E.. Baumgartner. Christine. Almeida. Osvaldo P.. Hogervorst. Eef. Trompet. Stella. Masaki. Kamal. Mooijaart. Simon P.. Gussekloo. Jacobijn. Peeters. Robin P.. Bauer. Douglas C.. Aujesky. Drahomir. Rodondi. Nicolas. Subclinical Thyroid Dysfunction and the Risk of Cognitive Decline: a Meta-Analysis of Prospective Cohort Studies. The Journal of Clinical Endocrinology & Metabolism. 101. 12. 30 September 2016. jc.2016–2129. 10.1210/jc.2016-2129. 27689250. 6287525.
  50. Lee . Sun Y. . Pearce . Elizabeth N. . Hyperthyroidism: A Review . JAMA . 17 October 2023 . 330 . 15 . 1472 . 10.1001/jama.2023.19052. 10873132 .
  51. 10.1210/mend-3-2-392 . Sakurai . A . vanc . Nakai . A. 1989 . Degroot . LJ . Expression of three forms of thyroid hormone receptor in human tissues . Molecular Endocrinology. 3 . 2. 392–9 . 2710139 . free .
  52. Shahrara . S . Drvota . V . Sylven . C. . vanc . 1999 . Organ specific expression of thyroid hormone receptor mRNA and protein in different human tissues . Biological & Pharmaceutical Bulletin. 22 . 10. 1027–33 . 10549850 . 10.1248/bpb.22.1027 . free .
  53. Geracioti . TD Jr . vanc . 2006 . How to identify hypothyroidism's psychiatric presentations . Current Psychiatry . 5 . 11. 98–117 .
  54. 10.1159/000289088 . Matsubayashi . S . Tamai . H . Matsumoto . Y . vanc . Tamagawa. 1996 . K . Mukuta . T . Morita . T . Kubo . C . Graves' disease after the onset of panic disorder . Psychotherapy and Psychosomatics. 65 . 5. 277–80 . 8893330 .
  55. Andersen S, Pedersen KM, Bruun NH, Laurberg P . Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease . The Journal of Clinical Endocrinology and Metabolism. 87 . 3 . 1068–72 . March 2002 . 11889165 . 10.1210/jc.87.3.1068. Pedersen . Bruun . Laurberg . free .
  56. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease. Kasagi K, Hatabu H, Tokuda Y, Iida Y, Endo K, Konishi J, Clin Endocrinol. 1988;29(4) 357.
  57. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission. Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K, The Journal of Clinical Endocrinology and Metabolism 1988;66(1) 103.
  58. Segni M, Leonardi E, Mazzoncini B, Pucarelli I, Pasquino AM . Special features of Graves' disease in early childhood . Thyroid. 9 . 1999 . 10524565 . 9. 871–7. 10.1089/thy.1999.9.871. Leonardi . Mazzoncini . Pucarelli . Pasquino .
  59. 10.1016/S0306-4530(99)00050-5 . Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism . Fahrenfort JJ, Wilterdink AM, van der Veen EA . Psychoneuroendocrinology. 2000 . 25 . 2 . 201–11 . 10674283. Wilterdink . Van Der Veen . 25205989 .
  60. Intellectual impairment after hyperthyroidism . Perrild H, Hansen JM, Arnung K, Olsen PZ, Danielsen U. . Acta Endocrinologica. 1986 . 112 . 2 . 185–91 . 3739553 . 10.1530/acta.0.1120185. Hansen . Arnung . Olsen . Danielsen .
  61. Graves' Disease: Quality Of Life And Occupational Disability . Katharina Ponto . Deutsches Ärzteblatt Online. 2009 . 106 . 17 . 283–9 . 19547630 . 2689575 . 10.3238/arztebl.2009.0283. vanc. 1. Pitz. S. Pfeiffer. N. Hommel. G. Weber. MM. Kahaly. GJ.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Signs and symptoms of Graves' disease".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.